Literature DB >> 30105447

Cell-specific gene therapy driven by an optimized hypoxia-regulated vector reduces choroidal neovascularization.

Manas R Biswal1,2, Howard M Prentice3,4, George W Smith1, Ping Zhu5, Yao Tong2, C Kathleen Dorey6, Alfred S Lewin2, Janet C Blanks1,7.   

Abstract

Aberrant growth of blood vessels in the choroid layer of the eye, termed choroidal neovascularization (CNV), is the pathological hallmark of exudative age-related macular degeneration (AMD), causing irreversible blindness among the elderly. Co-localization of proangiogenic factors and hypoxia inducible factors (HIF) in neovascular membranes from AMD eyes suggests the role of hypoxia in pathogenesis of CNV. In order to utilize hypoxic conditions in RPE for therapeutic purposes, we developed an optimized hypoxia regulated, RPE cell-specific gene therapy to inhibit choroidal neovascularization. An adeno-associated virus (AAV2) vector comprising a RPE-specific promoter and HIF-1 response elements (HRE) was designed to regulate production of human endostatin (a powerful angiostatic protein) in RPE. The vector was tested in a mouse model of laser-induced CNV using subretinal delivery. Spectral domain optical coherence tomography (SD-OCT) images from live mice and confocal images from lectin stained RPE flat mount sections demonstrated reduction in CNV areas by 80% compared to untreated eyes. Quantitative real-time polymerase chain reaction (qPCR) confirmed exogenous endostatin mRNA expression from the regulated vector that was significantly elevated 3, 7, and 14 days following laser treatment, but its expression was completely shut off after 45 days. Thus, RPE-specific, hypoxia-regulated delivery of anti-angiogenic proteins could be a valuable therapeutic approach to treat neovascular AMD at the time and in the ocular space where it arises. KEY POINTS: An optimized gene therapy vector targeting hypoxia and tissue-specific expression has been designed. The inhibitory role of gene therapy vector was tested in a mouse model of laser-induced CNV. An 80% reduction in choroidal neovascularization was achieved by the optimized vector. The expression of endostatin was limited to retinal pigment epithelium and regulated by hypoxia.

Entities:  

Keywords:  Adeno-associated virus; Age-related macular degeneration; Choroidal neovascularization; Endostatin; Gene therapy; Hypoxia responsive element; Retinal pigment epithelium

Mesh:

Substances:

Year:  2018        PMID: 30105447     DOI: 10.1007/s00109-018-1683-0

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  61 in total

Review 1.  Gene therapy for central nervous system repair.

Authors:  M Berry; L Barrett; L Seymour; A Baird; A Logan
Journal:  Curr Opin Mol Ther       Date:  2001-08

2.  Subretinal injections in rodent eyes: effects on electrophysiology and histology of rat retina.

Authors:  A M Timmers; H Zhang; A Squitieri; C Gonzalez-Pola
Journal:  Mol Vis       Date:  2001-06-22       Impact factor: 2.367

3.  An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris.

Authors:  Magali Saint-Geniez; Tomoki Kurihara; Eiichi Sekiyama; Angel E Maldonado; Patricia A D'Amore
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-19       Impact factor: 11.205

Review 4.  Structural and functional analysis of hypoxia-inducible factor 1.

Authors:  G L Semenza; F Agani; G Booth; J Forsythe; N Iyer; B H Jiang; S Leung; R Roe; C Wiener; A Yu
Journal:  Kidney Int       Date:  1997-02       Impact factor: 10.612

5.  Expression of hypoxia-inducible factor-1alpha and -2alpha in human choroidal neovascular membranes.

Authors:  Carl M Sheridan; Stephanie Pate; Paul Hiscott; David Wong; David M Pattwell; David Kent
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-07-10       Impact factor: 3.117

6.  The neuron-restrictive silencer factor (NRSF): a coordinate repressor of multiple neuron-specific genes.

Authors:  C J Schoenherr; D J Anderson
Journal:  Science       Date:  1995-03-03       Impact factor: 47.728

7.  Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury.

Authors:  Kazuaki Nishijima; Yin-Shan Ng; Lichun Zhong; John Bradley; William Schubert; Nobuo Jo; Jo Akita; Steven J Samuelsson; Gregory S Robinson; Anthony P Adamis; David T Shima
Journal:  Am J Pathol       Date:  2007-07       Impact factor: 4.307

8.  GDNF gene therapy attenuates retinal ischemic injuries in rats.

Authors:  Wei-Chi Wu; Chi-Chun Lai; Show-Li Chen; Ming-Hui Sun; Xiao Xiao; Tun-Lu Chen; Ray Jui-Fang Tsai; Shu-Wen Kuo; Yeou-Ping Tsao
Journal:  Mol Vis       Date:  2004-02-10       Impact factor: 2.367

9.  EIAV vector-mediated delivery of endostatin or angiostatin inhibits angiogenesis and vascular hyperpermeability in experimental CNV.

Authors:  K S Balaggan; K Binley; M Esapa; R E MacLaren; S Iqball; Y Duran; R A Pearson; O Kan; S E Barker; A J Smith; J W B Bainbridge; S Naylor; R R Ali
Journal:  Gene Ther       Date:  2006-06-13       Impact factor: 5.250

10.  Endogenous VEGF is required for visual function: evidence for a survival role on müller cells and photoreceptors.

Authors:  Magali Saint-Geniez; Arindel S R Maharaj; Tony E Walshe; Budd A Tucker; Eiichi Sekiyama; Tomoki Kurihara; Diane C Darland; Michael J Young; Patricia A D'Amore
Journal:  PLoS One       Date:  2008-11-03       Impact factor: 3.240

View more
  6 in total

Review 1.  From Bench to Bed: The Current Genome Editing Therapies for Glaucoma.

Authors:  Meihui He; Rong Rong; Dan Ji; Xiaobo Xia
Journal:  Front Cell Dev Biol       Date:  2022-05-16

Review 2.  The Different Facades of Retinal and Choroidal Endothelial Cells in Response to Hypoxia.

Authors:  Effat Alizadeh; Parviz Mammadzada; Helder André
Journal:  Int J Mol Sci       Date:  2018-12-03       Impact factor: 5.923

Review 3.  Viral-Vector-Delivered Anti-Angiogenic Therapies to the Eye.

Authors:  Sanna Koponen; Emmi Kokki; Kati Kinnunen; Seppo Ylä-Herttuala
Journal:  Pharmaceutics       Date:  2021-02-05       Impact factor: 6.321

4.  Delivery of nVEGFi using AAV8 for the treatment of neovascular age-related macular degeneration.

Authors:  Kaiqin She; Jing Su; Qingnan Wang; Yi Liu; Xiaomei Zhong; Xiu Jin; Qinyu Zhao; Jianlu Xiao; Ruiting Li; Hongxin Deng; Fang Lu; Yang Yang; Yuquan Wei
Journal:  Mol Ther Methods Clin Dev       Date:  2022-01-10       Impact factor: 6.698

Review 5.  The role of hypoxia-inducible factors in neovascular age-related macular degeneration: a gene therapy perspective.

Authors:  Parviz Mammadzada; Pablo M Corredoira; Helder André
Journal:  Cell Mol Life Sci       Date:  2019-12-31       Impact factor: 9.261

6.  IGFBP‑rP1‑silencing promotes hypoxia‑induced angiogenic potential of choroidal endothelial cells via the RAF/MEK/ERK signaling pathway.

Authors:  Shuting Zhu; Hong Wang; Zhihua Zhang; Mingming Ma; Zhi Zheng; Xun Xu; Tao Sun
Journal:  Mol Med Rep       Date:  2020-10-11       Impact factor: 2.952

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.